Conditional and reversible disruption of essential herpesvirus proteins.
about
Trial Watch:: Oncolytic viruses for cancer therapyTrial Watch-Oncolytic viruses and cancer therapyIntracellular context affects levels of a chemically dependent destabilizing domainUncoupling uncoating of herpes simplex virus genomes from their nuclear import and gene expression.Human cytomegalovirus protein pUL117 targets the mini-chromosome maintenance complex and suppresses cellular DNA synthesis.Herpesvirus BACs: past, present, and future.Activation of Innate and Adaptive Immunity by a Recombinant Human Cytomegalovirus Strain Expressing an NKG2D LigandHistone H3 lysine 4 methylation marks postreplicative human cytomegalovirus chromatin.The human cytomegalovirus UL51 protein is essential for viral genome cleavage-packaging and interacts with the terminase subunits pUL56 and pUL89.Development of a high-throughput assay to measure the neutralization capability of anti-cytomegalovirus antibodies.An intein-mediated modulation of protein stability system and its application to study human cytomegalovirus essential gene function.Trial watch: Oncolytic viruses for cancer therapyThe E3 ubiquitin ligase UBE3C enhances proteasome processivity by ubiquitinating partially proteolyzed substrates.Analysis of essential viral gene functions after highly efficient adenofection of cells with cloned human cytomegalovirus genomes.Oncolytic virotherapyMutual Interplay between the Human Cytomegalovirus Terminase Subunits pUL51, pUL56, and pUL89 Promotes Terminase Complex Formation.The Viral Bcl-2 Homologs of Kaposi's Sarcoma-Associated Herpesvirus and Rhesus Rhadinovirus Share an Essential Role for Viral Replication.Cytomegalovirus Vaccines: Current Status and Future Prospects.Remote and reversible inhibition of neurons and circuits by small molecule induced potassium channel stabilization.Cytomegalovirus pUL96 is critical for the stability of pp150-associated nucleocapsids.The human cytomegalovirus gene UL79 is required for the accumulation of late viral transcripts.The Essential Human Cytomegalovirus Proteins pUL77 and pUL93 Are Structural Components Necessary for Viral Genome Encapsidation.A replication-defective human cytomegalovirus vaccine for prevention of congenital infection.Human cytomegalovirus: bacterial artificial chromosome (BAC) cloning and genetic manipulation.Human cytomegalovirus early protein pUL21a promotes efficient viral DNA synthesis and the late accumulation of immediate-early transcripts.Cytomegalovirus vaccines under clinical developmentCytomegalovirus UL91 is essential for transcription of viral true late (γ2) genes.Progress toward Development of a Vaccine against Congenital Cytomegalovirus Infection.miRNA-mediated targeting of human cytomegalovirus reveals biological host and viral targets of IE2.Chemogenetic Tools for Causal Cellular and Neuronal Biology.Multiplex CRISPR/Cas9 system impairs HCMV replication by excising an essential viral gene.Drug-Inducible Control of Lethality Genes: A Low Background Destabilizing Domain Architecture Applied to the Gal4-UAS System in Drosophila.
P2860
Q27021951-67BFD78F-387F-4226-A277-6072C5817B76Q28072347-C1F41B85-B0CA-4C08-9FE0-6AF10519B196Q28483718-D52BB08A-C5DB-4684-9319-50ABA0D72215Q30430017-E38777ED-B28F-4EB8-88FF-6B7BB66F8076Q33545226-E3A1D1E9-BCF3-4C9F-861A-23CB36261FE5Q34247863-308FF87A-2DED-4AD7-9D5D-B60FA28F4229Q36210368-AA2F3F7A-DDC3-4F7C-B414-0490D01F48D3Q36246288-D218B02A-265C-45FB-8A22-354743F6141BQ36559969-69843D3E-7573-4CCD-BDDF-447B9548494BQ36757818-01185A97-2F79-4C72-B813-76E827FE3AF0Q36910786-776AEEFF-272A-4D69-94AE-F131449E920AQ37028023-8C4DFC82-13C1-4844-BFBF-ED5F34941129Q37348923-60CB929E-FF13-40EE-A6FB-E69A70024DCFQ37566765-2F0048D9-308B-4471-8A73-9A83916952D3Q38025263-CA483999-8DE1-4AE5-9CDC-19FC003F0B87Q38709692-7369638D-8E85-4BDF-B536-F3881EE9D894Q38722941-7C3E3B80-6711-417C-B985-C690F772587EQ38791353-3F17312C-A47E-42F2-A0C0-4148EF06BB76Q38804444-6863AD54-7375-4541-93B0-B57C91240CF2Q39540237-F4B71372-2ACE-44CE-A727-9C42C2532B00Q39582938-7AD9B0E4-8BE1-497C-B174-604B30369DF8Q39892577-844108EB-12B1-4ABB-8336-B3B49D3B6239Q40474474-F32566A8-26A1-4F6D-B0BD-673CE04F48B0Q40899325-FC31CE46-6A90-41C4-90FE-35405807661FQ42166179-504B2885-F38A-46E5-A1B7-7C4A1B4E7D41Q42380888-410B9D1E-F6F4-4FBF-BA75-8783B7609A09Q43079584-81081B34-ADA9-4544-93FA-A1B81FEB1CCEQ47115255-73E9723F-F484-4763-B759-76462FE791DCQ47552828-FB40DBC3-B3D9-4B79-9AAA-AB365EF2C358Q49917397-DEB79F07-B764-4D22-83C4-5535807D0F53Q49980151-887BB1C6-5DAB-4B8D-A99D-39E470666243Q55397782-6F4802C5-4B10-4BB8-9C3C-17444B18230E
P2860
Conditional and reversible disruption of essential herpesvirus proteins.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Conditional and reversible disruption of essential herpesvirus proteins.
@en
Conditional and reversible disruption of essential herpesvirus proteins.
@nl
type
label
Conditional and reversible disruption of essential herpesvirus proteins.
@en
Conditional and reversible disruption of essential herpesvirus proteins.
@nl
prefLabel
Conditional and reversible disruption of essential herpesvirus proteins.
@en
Conditional and reversible disruption of essential herpesvirus proteins.
@nl
P2093
P2860
P356
P1433
P1476
Conditional and reversible disruption of essential herpesvirus proteins
@en
P2093
Andreas Busche
Eva Maria Borst
Karen Wagner
P2860
P2888
P304
P356
10.1038/NMETH.1346
P577
2009-07-05T00:00:00Z